Pricing Log in Create free account
Friday 6 November 2026 Export BIO.B’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO.B Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.9%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

379.50 15.35 +4.22%
Market cap
$10.3B
P/E
9.9×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
3.24
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO.B) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 7 added · 1 removed · 22 modified
P2I1A: 1 added · 5 modified
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 9 added · 1 removed · 19 modified
P2I1A: 9 modified
8-K Jul 31, 2026 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Apr 21, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
8-K Feb 19, 2026 7.01 Regulation FD disclosure
10-K Dec 31, 2025 1: 3 added · 4 removed · 15 modified
1A: 1 added · 1 removed · 27 modified
7: 9 added · 15 removed · 23 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 29, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 29, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 31, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 1, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 7, 2025 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 29, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 15, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.